Chronology of p53 protein accumulation in gastric carcinogenesis

M E Craanen, P Blok, W Dekker, G J A Offerhaus, G N J Tytgat

Abstract
p53 Protein accumulation in early gastric carcinoma was studied in relation to the histological type (Lauren classification) and the type of growth pattern, including the chronology of p53 protein accumulation during carcinogenesis. Forty-five paraffin embedded gastrectomy specimens from early carcinomas were examined for the presence of chronic atrophic gastritis, subtypes of intestinal metaplasia, and dysplasia. The Lauren type and the type of growth pattern were reassessed for all early carcinomas. p53 Protein accumulation was examined using the monoclonal antibody DO-7. Complete absence of p53 protein accumulation was observed in normal gastric mucosa, chronic atrophic gastritis, and intestinal metaplasia, irrespective of subtype. In gastric dysplasia (one mild, two moderate, and one severe), only severe dysplasia was p53 positive. Intestinal type (n==20) and diffuse type early gastric carcinomas (n==25) were p53 positive in 70% and 52% of cases, respectively. Both tumour types differed significantly in the percentage of p53 positive tumour cells per tumour (p<0.01) and in staining intensity (p<0.05). No significant difference in p53 protein accumulation was found between early carcinomas with different types of growth pattern. It is concluded that p53 protein accumulation – usually reflecting missense p53 gene mutation – seems to be a late event in gastric carcinogenesis. Moreover, it is suggested that missense p53 gene mutation occurs in a final pathway common to both intestinal and diffuse type early gastric carcinoma. Finally, the types of growth pattern do not seem to differ in p53 protein accumulation.

Keywords: p53 protein accumulation, early gastric cancer, Lauren classification, growth pattern.

According to Lauren, gastric carcinoma can be divided into two main histological types – intestinal and diffuse type carcinoma.1 These two types not only differ morphologically, they have different clinical and epidemiological characteristics too.2,3 Moreover, the carcinogenesis of both types is considered to be different. Intestinal type gastric carcinoma is thought to be the end result of a multistep process leading from normal gastric mucosa via chronic active gastritis to chronic gastritis with variable degrees of atrophy, intestinal metaplasia, dysplasia, and ultimately to carcinoma. The diffuse type is thought to arise from the normal gastric mucosa, with no precursor lesion identified yet.4,5 Recent studies on the association of Helicobacter pylori and gastric carcinoma suggest, however, that H pylori induced gastritis may be a predisposing factor for both intestinal and diffuse types of gastric cancer.6-9 In colonic carcinogenesis, an accumulation of genetic changes have been described, with the progression from normal colonic mucosa via various (polyoid) precursor lesions to carcinoma.10 In contrast, the genetic changes at the various stages of gastric carcinogenesis remain to be explained. Research on the genetic basis of (gastrointestinal) malignancies has focused attention on the role of, among others, the p53 tumour suppressor gene in tumour development. To date there are very few reports on p53 protein accumulation – usually reflecting missense p53 gene mutation – in premalignant gastric lesions. Moreover, whereas several studies have reported mutations of the p53 gene in human gastric carcinoma and its lymph node metastases,11-13 early gastric carcinomas were not included. Finally, although the prognosis of surgically treated early gastric cancer is generally excellent,14 its metastatic potential and postoperative five year survival rate appear to be correlated with the type of growth pattern.15 Interestingly, nuclear p53 protein accumulation in gastric carcinoma has also been shown to correlate with a higher propensity for lymph node metastasis and to correlate with an unfavourable clinical outcome independent of tumour stage as measured by early relapse and death.16-18

In view of the above, we not only examined the chronology of p53 protein accumulation in gastric carcinogenesis, but also investigated p53 protein accumulation in relation to Lauren type and growth pattern of the early cancers.

Methods
Tissues
Forty-five gastrectomy specimens from patients with early gastric cancer were retrieved from the files. The tissues had been fixed in 10% formalin and processed to paraffin wax by routine methods. Chronic atrophic gastritis was diagnosed using the criteria of the Sydney classification.19,20 Whenever intestinal metaplasia was present in the mucosa, 5 μm sections were cut and stained with Alcian blue pH 2.5/periodic acid Schiff (AB pH 2.5/PAS) and high-iron-diamine/Alcian blue for subtyping of intestinal
metaplasia according to Filipe. Dysplasia was scored according to the criteria of the World Health Organization. Early gastric cancer was defined according to the Japanese Society of Gastrointestinal Endoscopy. The tumour histology according to Lauren, and the type of growth pattern according to Kodama et al. were reassessed using the original paraffin embedded, haematoxylin and eosin stained sections. In rare cases of disagreement, consensus was reached after discussion.

IMMUNOHISTOCHEMISTRY
To assess p53 protein accumulation, the commercially available monoclonal antibody DO-7 (DAKO, Glostrup, Denmark) was used in combination with the avidin-biotin-peroxidase method, as described by Hsu et al. DO-7, which can be used on (archival) paraffin embedded material, is a mouse monoclonal antibody raised against recombinant human wild type p53 protein expressed in Escherichia coli and recognises both wild type and mutant type p53 protein. The exact binding site of DO-7 is unknown, but is probably between amino acids 35–45 in the N-terminus of the p53 protein (DAKO data sheet).

Briefly, 4 μ sections were cut and dewaxed in xylene. After rehydration through alcohol, the sections were immersed in 0·3% hydrogen peroxidase in methanol for 30 minutes to block endogenous peroxidase activity. After washing with phosphate buffered saline (PBS), sections were treated with 10% normal goat serum to reduce non-specific antibody binding. All steps were carried out at room temperature. To improve p53 immunoreactivity, sections were treated with an antigen retrieval solution (10 mM citric acid monohydrate pH 6·0), heated in a microwave. After washing with PBS, DO-7 was applied for one hour. After further washing with PBS, sections were incubated with a biotinylated rabbit anti-mouse secondary antibody (DAKO). After further washing with PBS, peroxidase-conjugated streptavidin was applied. Peroxidase activity was demonstrated by adding diaminobenzidine as a chromogen. The sections were counterstained with haematoxylin. Negative control sections were processed without the primary antibody. Positive control sections were processed from a breast adenocarcinoma, previously shown to express high levels of p53 protein.

The proportion of tumour cells with nuclear p53 protein accumulation was arbitrarily divided into five groups: 0%, <10%, 10–30%, 30–60%, and >60% of the total tumour cell population per section. Four sections from each tumour were scored. A tumour was scored as p53 positive when at least 10% of the tumour cells showed nuclear p53 protein accumulation. In p53 positive tumours, the intensity of nuclear p53 immunostaining was graded as (1) weak but definitely visible and (2) strong and clearly visible. Ultimately, for each p53 positive early gastric cancer, a product score of % p53 positive cells×staining intensity was calculated as follows:

10–30% = 1, 30–60% = 2, 60% = 3, weak = 1 and strong = 2.

In cases of normal gastric mucosa, chronic active gastritis, intestinal metaplasia subtypes, and dysplasia, the same scoring criteria which was used in cases of early gastric cancer, were applied. Scoring was performed independently by two of the authors (MC/PB). In rare cases of disagreement, consensus was reached after discussion.

STATISTICS
The χ² test was used for statistical analysis, unless stated otherwise. A p value <0·05 was considered significant.

Results
HISTOLOGY
Normal gastric mucosa was observed in all gastrectomy specimens. Chronic active gastritis was present in 35 gastrectomy specimens. Since intestinal metaplasia was present multifocally, totals of 271 foci of type I intestinal metaplasia, 189 foci of type II intestinal metaplasia, and 53 foci of type III intestinal metaplasia were identified. Four areas of gastric dysplasia were found in the mucosa adjacent to the tumours and were graded as; mild (n = 1), moderate (n = 2), and severe (n = 1). There were 20 intestinal type early gastric cancers and 25 diffuse type early gastric cancers.

GROWTH PATTERN
Twenty seven early cancers (60%) were confined to the mucosa and 18 (40%) extended into the submucosa. According to growth pattern, there were 24 small mucosal type early gastric cancers (all limited to the mucosa), five superficial spreading type early gastric cancers (three mucosal, two submucosal), and 16 penetrating (Pen) type early gastric cancer (four Pen A type, 12 Pen B type).

p53 IMMUNOREACTIVITY
Without using the described antigen unmasking method, none of the sections, irrespective of the histological diagnosis, stained positively with DO-7 (data not shown). After pretreatment, the following results were obtained.
Complete absence of nuclear p53 protein accumulation (0% of p53 positive cells) was observed in normal gastric mucosa, chronic active gastritis, and all foci of intestinal metaplasia, irrespective of subtype. In cases of dysplasia, nuclear p53 protein accumulation was only found in the one area of severe dysplasia (Figure). Nuclear p53 protein accumulation was shown in 60% of early gastric cancers. When divided into histological type, 14 of 20 (70%) intestinal type and 13 of 25 (52%) diffuse type early gastric cancers were p53 positive (Table I).

The staining characteristics of both tumour types were significantly different (Table IIA and B). In 11 of 14 p53 positive intestinal type tumours and in three of 13 p53 positive diffuse type tumours (p<0.01), most of the tumour cells (>60%) showed nuclear p53 protein accumulation. Moreover, (the same) 11 p53 positive intestinal type early gastric cancers showed strong immunostaining, whereas only four of the p53 positive diffuse type early gastric cancer (all with >30% p53 positive cells) showed a similar staining intensity (p<0.05). The median product score (% p53 positive cells x staining intensity) was 6 for intestinal type and 1 for diffuse type early gastric cancer (Wilcoxon rank test: p<0.005). The tumour adjacent to the severe (p53 positive) dysplastic area, was a p53 positive intestinal type early gastric cancer (product score=6). The tumours adjacent to the mild/moderate (p53 negative) dysplastic areas were all p53 positive (two diffuse type with product scores of 2 and 1, respectively; one intestinal type with a product score of 6).

**Discussion**

Despite mounting evidence that immunohistochemical detection of p53 protein accumulation is not always synonymous with the presence of missense p53 gene mutation, p53 protein accumulation has been shown to be strongly associated with missense mutations in a highly conserved region (exons 5–8) of the p53 gene. Whereas wild type p53 protein has a very short half life, the mutant proteins have an extended half life and as a result can be readily detected by immunohistochemical analysis. To date, only three immunohistochemical studies have been published on pre-malignant gastric lesions and p53 protein accumulation. Chronic active gastritis and intestinal metaplasia were uniformly reported to be negative for p53 protein accumulation, although the exact number of scored intestinal metaplasia foci was not stated. Moreover, no division into the various intestinal metaplasia subtypes was made. Presumably, only subtype III, and not subtypes I and II, should be considered as a marker of premalignant change in the stomach. Our results clearly show that p53 protein accumulation does not occur in chronic active gastritis and the various intestinal metaplasia subtypes. This finding does not necessarily deny the premalignant potential of chronic active gastritis and intestinal metaplasia (type III in particular), but rather suggests that p53 protein accumulation occurs beyond the stage of chronic active gastritis and intestinal metaplasia formation. In our study, p53 protein accumulation was found only in severe gastric dysplasia. Although the very small number of areas of gastric dysplasia precludes firm conclusions, our data seem to be in line with the results of the former three studies. They not only reported p53 protein accumulation in gastric dysplasia, but also that the frequency of p53 positivity increased with the severity of dysplasia. Similar findings have been reported in dysplastic Barrett’s epithelium.

Comparison of different immunohistochemical studies is fraught with pitfalls and difficulties. Differences in tissue fixation, antibodies used or different scoring criteria, or

---

**TABLE I**

<table>
<thead>
<tr>
<th>intestinal type EGC (n=20)</th>
<th>p53 Positive (%)</th>
<th>0</th>
<th>&gt;60</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>p53 Negative (%)</td>
<td>70*</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Diffuse type EGC (n=25)</td>
<td>52*</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Dysplasia: MILD (n=2)</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Moderate (n=2)</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Severe (n=1)</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Intestinal metaplasia foci:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Type I (n=271)</td>
<td>271</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Type II (n=189)</td>
<td>189</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Type III (n=35)</td>
<td>53</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Chronic active gastritis (n=35)</td>
<td>35</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>Normal mucosa (n=45)</td>
<td>45</td>
<td>45</td>
</tr>
</tbody>
</table>

---

**TABLE II**

<table>
<thead>
<tr>
<th>A: Cells with nuclear p53 protein accumulation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
</tr>
<tr>
<td>Intestinal type EGC (n=20)</td>
</tr>
<tr>
<td>Diffuse type EGC (n=25)</td>
</tr>
<tr>
<td>Dysplasia (n=4)</td>
</tr>
</tbody>
</table>

| Intestinal metaplasia foci: | |
|--------------------------------|
| Type I (n=271) | 271 | 3 |
| Type II (n=189) | 189 | 1 |
| Type III (n=35) | 35 | 35 |
| Chronic active gastritis (n=35) | 35 | 35 |
| Normal mucosa (n=45) | 45 | 45 |

<table>
<thead>
<tr>
<th>B: Intensity of nuclear p53 immunoreactivity in p53+ve lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weak</td>
</tr>
<tr>
<td>Intestinal type EGC (n=14)</td>
</tr>
<tr>
<td>Diffuse type EGC (n=13)</td>
</tr>
<tr>
<td>Dysplasia (n=1)</td>
</tr>
</tbody>
</table>

---

**TABLE III**

<table>
<thead>
<tr>
<th>Growth pattern</th>
<th>No</th>
<th>p53 Positive (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small mucosal:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucosa limited</td>
<td>24</td>
<td>50</td>
</tr>
<tr>
<td>Submucosa involved</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Superficial spreading:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucosa limited</td>
<td>3</td>
<td>33</td>
</tr>
<tr>
<td>Submucosa involved</td>
<td>2</td>
<td>100</td>
</tr>
<tr>
<td>Penetrating type:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type A</td>
<td>4</td>
<td>50</td>
</tr>
<tr>
<td>Type B</td>
<td>12</td>
<td>83</td>
</tr>
</tbody>
</table>
both, for example, may lead to biased conclusions. We used monoclonal antibody DO-7, whereas other investigators used either polyclonal antibody CM-133, 34 or monoclonal antibody Pab 1801.35 All three antibodies recognise both wild type and mutant type p53 protein, despite differences in the epitopes recognised.40-42 DO-7, however, has been reported to be superior to both CM-1 or Pab 1801 on formalin fixed, paraffin embedded tissues in detecting missense p53 gene mutations, especially when combined with target unmasking fluid.43 Our data therefore suggest that missense p53 gene mutation is a late event in gastric carcinogenesis. In contrast, the only study to date which has used p53 gene mutational analysis (single strand conformation polymorphism with direct DNA sequencing) as an adjunct to immunohistochemistry has suggested that p53 gene mutation is an early pathogenic event in gastric carcinogenesis. Missense mutations, however, were found only from dysplasia onwards. Moreover, the mutations found in three of eight cases of intestinal metaplasia did not change the amino acid sequence of the p53 protein, thereby leaving the p53 protein in its wild type form. Finally, it was not stated whether or not the intron 5 mutation in intestinal metaplasia affected the splice site acceptor region. Its conclusion, therefore, that p53 gene mutation is an early instead of a late pathogenic event in gastric carcinogenesis seems unlikely.44 Apparently, p53 is not involved in the (early) progression from metaplastic to dysplastic epithelium, but is involved in the malignant transformation from dysplasia onwards.

According to our criteria, 60% of early gastric cancers were p53 positive, and similar percentages have been reported in both early and advanced carcinomas.16 33 No significant difference was found in the proportion of p53 positive tumours between intestinal and diffuse type early gastric cancers. This finding does not necessarily preclude the possibility of a different pathogenesis of both tumour types but could merely reflect the occurrence of missense p53 gene mutations during a final common pathway of genetic alterations.

Whether or not both tumour types differ in the occurrence of nonsense p53 gene mutations remains unanswered in our study. Immunohistochemistry can not generally detect these mutations since they lead to stop codon formation and premature termination of translation. Interestingly, significant differences in immunostaining characteristics were observed between both types of early gastric cancer, best exemplified by the median product score of the % p53 positive cells×staining intensity. Of course, it is tempting to speculate that intestinal and diffuse type early gastric cancers differ in their p53 mutational spectrum or in the expression of viral or cellular proteins that interact with p53. Furthermore, differences in the expression levels of the p53 gene in both tumour types, in cell cycle kinetics, and finally in the p53 protein degradation pathway might be considered. However, one should also cautiously include the possibility that microwave pretreatment has influenced results, since this technique may lower the immunohistochemical detection threshold of the p53 protein45 and may influence immunostaining results appreciably, as has been shown by Lambkin et al.46 As a result, it cannot entirely be ruled out that in some cases, especially in those with weak nuclear staining intensity, stabilised inactivated wild type p53 protein is being detected instead of mutant forms. Ideally, therefore, one should combine microwave pretreatment with the use of an antibody that specifically recognises mutant forms, as has been reported for Pab 240,47 but unfortunately this antibody can not be applied to formalin fixed, paraffin embedded tissues.42 43

It has been reported that p53 protein accumulation in gastric carcinoma is correlated with a higher propensity for lymph node metastasis and with an unfavourable clinical outcome independent of tumour stage, as measured by early relapse and death.16-18 Moreover, recent findings on the role of p53 in the apoptotic response of cells to genotoxic stimuli such as radiation and anticancer agents,48-50 lend further support to the concept that p53 protein acts as a tumour suppressor. A distinct group of gastric carcinomas with a higher malignant potential than p53 negative gastric carcinomas. Since, in cases of early gastric cancer, the type of growth pattern may also strongly influence malignant potential and clinical outcome, we examined whether growth patterns and p53 protein accumulation are correlated. Whereas the pen A type, in contrast to the other growth types, has been reported to have a high propensity for blood vessel invasion and lymph node metastasis and to have the worst prognosis after surgery due to early postoperative hepatic metastasis,14 we found no significant difference in p53 protein accumulation between the various growth types.

In conclusion, p53 protein accumulation – usually reflecting missense p53 gene mutation – should be considered as a late event in gastric carcinogenesis. Moreover, we suggest that missense p53 gene mutation occurs in a final pathway of genetic alterations common to both intestinal and diffuse type early gastric cancer. Finally, it seems that mechanisms other than p53 protein accumulation underlie the reported differences in biological behaviour of early gastric carcinomas with different types of growth pattern.
Chronology of p53 protein accumulation in gastric carcinogenesis.

M E Craanen, P Blok, W Dekker, G J Offerhaus and G N Tytgat

Gut 1995 36: 848-852
doi: 10.1136/gut.36.6.848

Updated information and services can be found at:
http://gut.bmj.com/content/36/6/848

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Stomach and duodenum (1689)
Pancreatic cancer (660)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/